Skip to main content
Premium Trial:

Request an Annual Quote

Allan Comstock, Andrew von Eschenbach, Lester Crawford, Douglas Throckmorton, Cheri Walker


Caliper Life Sciences has named Allan Comstock to its board of directors, the Hopkinton, Mass.-based company said this week. Comstock will also serve as the audit committee chair, Caliper said.

Previously, Comstock was vice president and controller of Atlantic Richfield Company for seven years before retiring in 2000. He has also held numerous other positions at ARCO, Caliper said. Comstock holds an MBA and BS from Southern Illinois University.

Andrew von Eschenbach has been named acting commissioner of the US Food and Drug Administration, following the resignation of former commissioner Lester Crawford in September.

Von Eschenbach has been director of the National Cancer Institute, part of the National Institutes of Health, since January 2002. Before that, he worked as a doctor and executive at the MD Anderson Cancer Center in Houston. Von Eschenbach has said that he intends to act as both head of the FDA and director of NCI.

Douglas Throckmorton has been named deputy director of the Center for Drug Evaluation and Research by the FDA. Throckmorton joined the FDA in 1997 and has been acting deputy director of CDER since May 2004.

Before joining the FDA, Throckmorton practiced medicine and held academic appointments at the Medical College of Georgia and the VA Medical Center in Augusta, GA.

Cheri Walker has been named vice president of mergers and acquisitions of Qiagen. Walker joined the firm in late September from Invitrogen, where she most recently held the position of vice president of proteomics. She had joined Invitrogen in December 2003 as vice president, corporate development. Prior to working at Invitrogen, Walker was an equity analyst with Deutsche Bank covering the life sciences tools industry.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.